Darinaparsin

Generic Name
Darinaparsin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C12H22AsN3O6S
CAS Number
69819-86-9
Unique Ingredient Identifier
9XX54M675G
Indication

Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), solid tumors, multiple myeloma, and liver cancer.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

Phase 1
Withdrawn
Conditions
Lymphoma
Interventions
Drug: darinaparsin
Drug: CHOP
First Posted Date
2010-06-08
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Registration Number
NCT01139359

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: darinaparsin
First Posted Date
2010-06-08
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
12
Registration Number
NCT01139346

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

Phase 2
Conditions
HEPATOCELLULAR CARCINOMA
Interventions
Drug: Darinaparsin
First Posted Date
2007-01-18
Last Posted Date
2013-11-14
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
15
Registration Number
NCT00423306

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

First Posted Date
2007-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
50
Registration Number
NCT00421213
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy